Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation

Trial Profile

Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Melphalan; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms CARTHADEX
  • Sponsors Erasmus MC; Onyx Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2016 Results of 4 dose levels presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 29 Nov 2016 Data from this trial will be presented at the 58th annual meeting of the American Society of Hematology (ASH) 2016, according to a SkylineDx media release.
    • 04 Aug 2015 Planned End Date changed from 15 Jan 2012 to 1 Apr 2018 as reported by Netherlands Trial Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top